{"id":1488,"date":"2026-09-07T16:16:46","date_gmt":"2026-09-07T14:16:46","guid":{"rendered":"https:\/\/amyloidosisalliance.local\/essais-cliniques\/"},"modified":"2026-09-29T11:06:38","modified_gmt":"2026-09-29T09:06:38","slug":"essais-cliniques","status":"publish","type":"page","link":"https:\/\/amyloidosisalliance.pacom1.com\/fr\/essais-cliniques\/","title":{"rendered":"Essais cliniques"},"content":{"rendered":"\n<nav aria-label=\"Breadcrumb\" class=\"wp-block-group aa-breadcrumb is-layout-flow wp-block-group-is-layout-flow\">\n<div class=\"aa-inner\"><a href=\"https:\/\/amyloidosisalliance.pacom1.com\/fr\/\">Accueil<\/a><span class=\"aa-breadcrumb__sep\">\u203a<\/span><span class=\"aa-breadcrumb__current\">Essais cliniques<\/span><\/div>\n<\/nav>\n\n<section class=\"wp-block-group aa-page-hero is-layout-flow wp-block-group-is-layout-flow\">\n<div class=\"wp-block-group aa-inner is-layout-flow wp-block-group-is-layout-flow\">\n<div class=\"wp-block-group aa-page-hero__grid is-layout-flow wp-block-group-is-layout-flow\">\n<div class=\"wp-block-group is-layout-flow wp-block-group-is-layout-flow\">\n<p class=\"aa-overline wp-block-paragraph\">Recherche<\/p>\n\n\n\n<h1 class=\"wp-block-heading\">Essais cliniques<\/h1>\n\n\n\n<p class=\"aa-lead wp-block-paragraph\">Toutes les \u00e9tudes sur l\u2019amylose qui recrutent, vont ouvrir ou recrutent sur invitation, partout dans le monde, directement issues de ClinicalTrials.gov et mises \u00e0 jour chaque jour.<\/p>\n\n\n\n<p class=\"aa-trial-warn wp-block-paragraph\"><strong>Une information, pas un avis m\u00e9dical.<\/strong> L\u2019Alliance ne conduit pas ces \u00e9tudes et ne peut pas vous y inscrire. Si un essai vous semble pertinent, parlez-en au m\u00e9decin qui suit votre amylose.<\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-group aa-page-hero__photo is-layout-flow wp-block-group-is-layout-flow\">\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"1707\" height=\"1707\" src=\"https:\/\/amyloidosisalliance.pacom1.com\/wp-content\/uploads\/2026\/09\/hans-reniers-lQGJCMY5qcM-unsplash-scaled-e1788792920766.jpg\" alt=\"\" class=\"wp-image-1000\" srcset=\"https:\/\/amyloidosisalliance.pacom1.com\/wp-content\/uploads\/2026\/09\/hans-reniers-lQGJCMY5qcM-unsplash-scaled-e1788792920766.jpg 1707w, https:\/\/amyloidosisalliance.pacom1.com\/wp-content\/uploads\/2026\/09\/hans-reniers-lQGJCMY5qcM-unsplash-scaled-e1788792920766-300x300.jpg 300w, https:\/\/amyloidosisalliance.pacom1.com\/wp-content\/uploads\/2026\/09\/hans-reniers-lQGJCMY5qcM-unsplash-scaled-e1788792920766-1024x1024.jpg 1024w, https:\/\/amyloidosisalliance.pacom1.com\/wp-content\/uploads\/2026\/09\/hans-reniers-lQGJCMY5qcM-unsplash-scaled-e1788792920766-150x150.jpg 150w, https:\/\/amyloidosisalliance.pacom1.com\/wp-content\/uploads\/2026\/09\/hans-reniers-lQGJCMY5qcM-unsplash-scaled-e1788792920766-768x768.jpg 768w, https:\/\/amyloidosisalliance.pacom1.com\/wp-content\/uploads\/2026\/09\/hans-reniers-lQGJCMY5qcM-unsplash-scaled-e1788792920766-1536x1536.jpg 1536w\" sizes=\"auto, (max-width: 1707px) 100vw, 1707px\" \/><\/figure>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n\n<section id=\"trials\" class=\"wp-block-group aa-section aa-section--cream aa-trials-page is-layout-flow wp-block-group-is-layout-flow\">\n<div class=\"wp-block-group aa-inner is-layout-flow wp-block-group-is-layout-flow\">\n<h2 class=\"wp-block-heading\">\u00c9tudes en cours de recrutement et \u00e0 venir<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">La liste couvre les amyloses AL, ATTR et AA ainsi que l\u2019angiopathie amylo\u00efde c\u00e9r\u00e9brale. Chaque fiche indique o\u00f9 en est l\u2019\u00e9tude\u00a0: ouverte \u00e0 toute personne qui remplit ses crit\u00e8res, pas encore ouverte, ou r\u00e9serv\u00e9e aux personnes invit\u00e9es par les investigateurs. Les \u00e9tudes qui se terminent disparaissent simplement de la liste.<\/p>\n\n\n<div class=\"aa-trials aa-no-reveal wp-block-aa-clinical-trials\" data-endpoint=\"https:\/\/amyloidosisalliance.pacom1.com\/fr\/wp-json\/aa\/v1\/trials\" data-page=\"0\" data-per-page=\"12\"><form class=\"aa-trial-filters\" method=\"get\" action=\"https:\/\/amyloidosisalliance.pacom1.com\/fr\/\"><p class=\"aa-trial-filters__field\"><label class=\"aa-trial-filters__label\" for=\"aa-trial-t_type\">Type d&#039;amylose<\/label><select class=\"aa-trial-filters__select\" id=\"aa-trial-t_type\" name=\"t_type\"><option value=\"\">Tous les types<\/option><option value=\"attr\">ATTR (transthyr\u00e9tine)<\/option><option value=\"al\">AL (cha\u00eenes l\u00e9g\u00e8res)<\/option><option value=\"aa\">AA (secondaire)<\/option><option value=\"caa\">Angiopathie amylo\u00efde c\u00e9r\u00e9brale<\/option><option value=\"unspecified\">Non pr\u00e9cis\u00e9<\/option><\/select><\/p><p class=\"aa-trial-filters__field\"><label class=\"aa-trial-filters__label\" for=\"aa-trial-t_country\">Pays<\/label><select class=\"aa-trial-filters__select\" id=\"aa-trial-t_country\" name=\"t_country\"><option value=\"\">Tous les pays<\/option><option value=\"Argentina\">Argentina<\/option><option value=\"Australia\">Australia<\/option><option value=\"Austria\">Austria<\/option><option value=\"Belgium\">Belgium<\/option><option value=\"Brazil\">Brazil<\/option><option value=\"Bulgaria\">Bulgaria<\/option><option value=\"Canada\">Canada<\/option><option value=\"Chile\">Chile<\/option><option value=\"China\">China<\/option><option value=\"Croatia\">Croatia<\/option><option value=\"Cyprus\">Cyprus<\/option><option value=\"Czechia\">Czechia<\/option><option value=\"Denmark\">Denmark<\/option><option value=\"Estonia\">Estonia<\/option><option value=\"Finland\">Finland<\/option><option value=\"France\">France<\/option><option value=\"Germany\">Germany<\/option><option value=\"Greece\">Greece<\/option><option value=\"Hong Kong\">Hong Kong<\/option><option value=\"Hungary\">Hungary<\/option><option value=\"Ireland\">Ireland<\/option><option value=\"Israel\">Israel<\/option><option value=\"Italy\">Italy<\/option><option value=\"Japan\">Japan<\/option><option value=\"Latvia\">Latvia<\/option><option value=\"Lithuania\">Lithuania<\/option><option value=\"Malaysia\">Malaysia<\/option><option value=\"Martinique\">Martinique<\/option><option value=\"Mexico\">Mexico<\/option><option value=\"Netherlands\">Netherlands<\/option><option value=\"New Zealand\">New Zealand<\/option><option value=\"Norway\">Norway<\/option><option value=\"Poland\">Poland<\/option><option value=\"Portugal\">Portugal<\/option><option value=\"Romania\">Romania<\/option><option value=\"Singapore\">Singapore<\/option><option value=\"Slovakia\">Slovakia<\/option><option value=\"Slovenia\">Slovenia<\/option><option value=\"South Korea\">South Korea<\/option><option value=\"Spain\">Spain<\/option><option value=\"Sweden\">Sweden<\/option><option value=\"Switzerland\">Switzerland<\/option><option value=\"Taiwan\">Taiwan<\/option><option value=\"Thailand\">Thailand<\/option><option value=\"Turkey (T\u00fcrkiye)\">Turkey (T\u00fcrkiye)<\/option><option value=\"United Kingdom\">United Kingdom<\/option><option value=\"United States\">United States<\/option><option value=\"Uruguay\">Uruguay<\/option><\/select><\/p><p class=\"aa-trial-filters__field\"><label class=\"aa-trial-filters__label\" for=\"aa-trial-t_kind\">Type d\u2019\u00e9tude<\/label><select class=\"aa-trial-filters__select\" id=\"aa-trial-t_kind\" name=\"t_kind\"><option value=\"\">Toutes les \u00e9tudes<\/option><option value=\"INTERVENTIONAL\">Interventionnelle (traitement)<\/option><option value=\"OBSERVATIONAL\">Observationnelle (registre, imagerie)<\/option><\/select><\/p><p class=\"aa-trial-filters__field\"><label class=\"aa-trial-filters__label\" for=\"aa-trial-t_status\">Statut<\/label><select class=\"aa-trial-filters__select\" id=\"aa-trial-t_status\" name=\"t_status\"><option value=\"\">Tous les statuts<\/option><option value=\"RECRUITING\">Recrute<\/option><option value=\"NOT_YET_RECRUITING\">Pas encore ouverte<\/option><option value=\"ENROLLING_BY_INVITATION\">Sur invitation<\/option><\/select><\/p><p class=\"aa-trial-filters__actions\"><button type=\"submit\" class=\"aa-trial-filters__submit\">Filtrer<\/button><a class=\"aa-trial-filters__reset\" href=\"https:\/\/amyloidosisalliance.pacom1.com\/fr\/\" hidden>Effacer les filtres<\/a><\/p><\/form><div class=\"aa-trial-results\" aria-live=\"polite\" aria-busy=\"false\"><p class=\"aa-trial-count\">Affichage de 1 \u00e0 12 sur 202 essais<\/p><div class=\"aa-trial-grid\"><article class=\"aa-trial-card\"><p class=\"aa-trial-card__flags\"><span class=\"aa-trial-status aa-trial-status--recruiting\">Recrute<\/span><span class=\"aa-trial-type\">Non pr\u00e9cis\u00e9<\/span><\/p><h3 class=\"aa-trial-card__title\"><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06887283\" target=\"_blank\" rel=\"noopener noreferrer\">Essen Amyloidosis Registry<span class=\"screen-reader-text\"> (s\u2019ouvre sur ClinicalTrials.gov)<\/span><\/a><\/h3><p class=\"aa-trial-card__summary\">The Essen Amyloidosis Registry (EAR) is a prospective, observational registry designed to collect comprehensive clinical data on patients diagnosed with systemic amyloidosis. The registry\u2026<\/p><dl class=\"aa-trial-card__facts\"><div><dt>\u00c9tude<\/dt><dd>Observationnelle (registre, imagerie)<\/dd><\/div><div><dt>Promoteur<\/dt><dd>University Hospital, Essen<\/dd><\/div><\/dl><p class=\"aa-trial-card__places\"><span class=\"screen-reader-text\">Recrute en : <\/span><span class=\"aa-trial-place\">Germany<\/span><\/p><p class=\"aa-trial-card__foot\"><span class=\"aa-trial-card__nct\">NCT06887283<\/span><span class=\"aa-trial-card__updated\">Mis \u00e0 jour le 6 novembre 2026<\/span><\/p><\/article><article class=\"aa-trial-card\"><p class=\"aa-trial-card__flags\"><span class=\"aa-trial-status aa-trial-status--recruiting\">Recrute<\/span><span class=\"aa-trial-type\">AL (cha\u00eenes l\u00e9g\u00e8res)<\/span><\/p><h3 class=\"aa-trial-card__title\"><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07250269\" target=\"_blank\" rel=\"noopener noreferrer\">Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis<span class=\"screen-reader-text\"> (s\u2019ouvre sur ClinicalTrials.gov)<\/span><\/a><\/h3><p class=\"aa-trial-card__summary\">This is a Phase 1b open-label, multicenter, non-randomized study of GC012F, a CD19\/BCMA dual CAR T cell therapy, in adult participants with relapsed\/refractory AL\u2026<\/p><dl class=\"aa-trial-card__facts\"><div><dt>\u00c9tude<\/dt><dd>Interventionnelle (traitement)<\/dd><\/div><div><dt>Phase<\/dt><dd>Phase 1<\/dd><\/div><div><dt>Promoteur<\/dt><dd>Gracell Biotechnologies (Shanghai) Co., Ltd.<\/dd><\/div><\/dl><p class=\"aa-trial-card__places\"><span class=\"screen-reader-text\">Recrute en : <\/span><span class=\"aa-trial-place\">China<\/span><\/p><p class=\"aa-trial-card__foot\"><span class=\"aa-trial-card__nct\">NCT07250269<\/span><span class=\"aa-trial-card__updated\">Mis \u00e0 jour le 6 novembre 2026<\/span><\/p><\/article><article class=\"aa-trial-card\"><p class=\"aa-trial-card__flags\"><span class=\"aa-trial-status aa-trial-status--recruiting\">Recrute<\/span><span class=\"aa-trial-type\">Non pr\u00e9cis\u00e9<\/span><\/p><h3 class=\"aa-trial-card__title\"><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07589595\" target=\"_blank\" rel=\"noopener noreferrer\">A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)<span class=\"screen-reader-text\"> (s\u2019ouvre sur ClinicalTrials.gov)<\/span><\/a><\/h3><p class=\"aa-trial-card__summary\">The main purpose of this study is to evaluate whether treatment with donanemab slows the progression of cognitive (how we think, learn, remember, pay\u2026<\/p><dl class=\"aa-trial-card__facts\"><div><dt>\u00c9tude<\/dt><dd>Interventionnelle (traitement)<\/dd><\/div><div><dt>Phase<\/dt><dd>Phase 2<\/dd><\/div><div><dt>Promoteur<\/dt><dd>Eli Lilly and Company<\/dd><\/div><\/dl><p class=\"aa-trial-card__places\"><span class=\"screen-reader-text\">Recrute en : <\/span><span class=\"aa-trial-place\">Japan<\/span><span class=\"aa-trial-place\">South Korea<\/span><span class=\"aa-trial-place\">Taiwan<\/span><span class=\"aa-trial-place\">United States<\/span><\/p><p class=\"aa-trial-card__foot\"><span class=\"aa-trial-card__nct\">NCT07589595<\/span><span class=\"aa-trial-card__updated\">Mis \u00e0 jour le 4 novembre 2026<\/span><\/p><\/article><article class=\"aa-trial-card\"><p class=\"aa-trial-card__flags\"><span class=\"aa-trial-status aa-trial-status--recruiting\">Recrute<\/span><span class=\"aa-trial-type\">ATTR (transthyr\u00e9tine)<\/span><\/p><h3 class=\"aa-trial-card__title\"><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06128629\" target=\"_blank\" rel=\"noopener noreferrer\">MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)<span class=\"screen-reader-text\"> (s\u2019ouvre sur ClinicalTrials.gov)<\/span><\/a><\/h3><p class=\"aa-trial-card__summary\">To evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in participants with ATTR-CM.<\/p><dl class=\"aa-trial-card__facts\"><div><dt>\u00c9tude<\/dt><dd>Interventionnelle (traitement)<\/dd><\/div><div><dt>Phase<\/dt><dd>Phase 3<\/dd><\/div><div><dt>Promoteur<\/dt><dd>Intellia Therapeutics<\/dd><\/div><\/dl><p class=\"aa-trial-card__places\"><span class=\"screen-reader-text\">Recrute en : <\/span><span class=\"aa-trial-place\">Argentina<\/span><span class=\"aa-trial-place\">Australia<\/span><span class=\"aa-trial-place\">Austria<\/span><span class=\"aa-trial-place\">Belgium<\/span><span class=\"aa-trial-place aa-trial-place--more\">+22<\/span><\/p><p class=\"aa-trial-card__foot\"><span class=\"aa-trial-card__nct\">NCT06128629<\/span><span class=\"aa-trial-card__updated\">Mis \u00e0 jour le 4 novembre 2026<\/span><\/p><\/article><article class=\"aa-trial-card\"><p class=\"aa-trial-card__flags\"><span class=\"aa-trial-status aa-trial-status--recruiting\">Recrute<\/span><span class=\"aa-trial-type\">ATTR (transthyr\u00e9tine)<\/span><\/p><h3 class=\"aa-trial-card__title\"><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06978660\" target=\"_blank\" rel=\"noopener noreferrer\">Multicenter Study for the Validation of an AI-based ECG Platform for Early Cardiac Amyloidosis Diagnosis<span class=\"screen-reader-text\"> (s\u2019ouvre sur ClinicalTrials.gov)<\/span><\/a><\/h3><p class=\"aa-trial-card__summary\">CONCERTO is a retrospective, observational, multicentric and single-arm study to perform an external validation of the cloud-based and AI-powered electrocardiogram (ECG) analysis platform, named\u2026<\/p><dl class=\"aa-trial-card__facts\"><div><dt>\u00c9tude<\/dt><dd>Observationnelle (registre, imagerie)<\/dd><\/div><div><dt>Promoteur<\/dt><dd>Idoven 1903 S.L.<\/dd><\/div><\/dl><p class=\"aa-trial-card__places\"><span class=\"screen-reader-text\">Recrute en : <\/span><span class=\"aa-trial-place\">France<\/span><span class=\"aa-trial-place\">Germany<\/span><span class=\"aa-trial-place\">Spain<\/span><span class=\"aa-trial-place\">United Kingdom<\/span><span class=\"aa-trial-place aa-trial-place--more\">+1<\/span><\/p><p class=\"aa-trial-card__foot\"><span class=\"aa-trial-card__nct\">NCT06978660<\/span><span class=\"aa-trial-card__updated\">Mis \u00e0 jour le 4 novembre 2026<\/span><\/p><\/article><article class=\"aa-trial-card\"><p class=\"aa-trial-card__flags\"><span class=\"aa-trial-status aa-trial-status--recruiting\">Recrute<\/span><span class=\"aa-trial-type\">AL (cha\u00eenes l\u00e9g\u00e8res)<\/span><\/p><h3 class=\"aa-trial-card__title\"><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06971380\" target=\"_blank\" rel=\"noopener noreferrer\">Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis<span class=\"screen-reader-text\"> (s\u2019ouvre sur ClinicalTrials.gov)<\/span><\/a><\/h3><p class=\"aa-trial-card__summary\">A Phase II study of HBI0101 (NXC-201) BCMA-CART in Multiple Myeloma and Light-chain Amyloidosis Patients. The goal of the study is to evaluate the\u2026<\/p><dl class=\"aa-trial-card__facts\"><div><dt>\u00c9tude<\/dt><dd>Interventionnelle (traitement)<\/dd><\/div><div><dt>Phase<\/dt><dd>Phase 2<\/dd><\/div><div><dt>Promoteur<\/dt><dd>Polina Stepensky<\/dd><\/div><\/dl><p class=\"aa-trial-card__places\"><span class=\"screen-reader-text\">Recrute en : <\/span><span class=\"aa-trial-place\">Israel<\/span><\/p><p class=\"aa-trial-card__foot\"><span class=\"aa-trial-card__nct\">NCT06971380<\/span><span class=\"aa-trial-card__updated\">Mis \u00e0 jour le 4 novembre 2026<\/span><\/p><\/article><article class=\"aa-trial-card\"><p class=\"aa-trial-card__flags\"><span class=\"aa-trial-status aa-trial-status--recruiting\">Recrute<\/span><span class=\"aa-trial-type\">Non pr\u00e9cis\u00e9<\/span><\/p><h3 class=\"aa-trial-card__title\"><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04776824\" target=\"_blank\" rel=\"noopener noreferrer\">Swiss Cardiac Amyloidosis REgistry (Swiss-CARE)<span class=\"screen-reader-text\"> (s\u2019ouvre sur ClinicalTrials.gov)<\/span><\/a><\/h3><p class=\"aa-trial-card__summary\">Cardiac transthyretin amyloidosis (ATTR), caused by ventricular depositions of misfolded transthyretin, results in an infiltrative cardiomyopathy, progressing from pronounced myocardial wall thickening, diastolic and\u2026<\/p><dl class=\"aa-trial-card__facts\"><div><dt>\u00c9tude<\/dt><dd>Observationnelle (registre, imagerie)<\/dd><\/div><div><dt>Promoteur<\/dt><dd>Insel Gruppe AG, University Hospital Bern<\/dd><\/div><\/dl><p class=\"aa-trial-card__places\"><span class=\"screen-reader-text\">Recrute en : <\/span><span class=\"aa-trial-place\">Switzerland<\/span><\/p><p class=\"aa-trial-card__foot\"><span class=\"aa-trial-card__nct\">NCT04776824<\/span><span class=\"aa-trial-card__updated\">Mis \u00e0 jour le 4 novembre 2026<\/span><\/p><\/article><article class=\"aa-trial-card\"><p class=\"aa-trial-card__flags\"><span class=\"aa-trial-status aa-trial-status--recruiting\">Recrute<\/span><span class=\"aa-trial-type\">AL (cha\u00eenes l\u00e9g\u00e8res)<\/span><\/p><h3 class=\"aa-trial-card__title\"><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05652335\" target=\"_blank\" rel=\"noopener noreferrer\">A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis<span class=\"screen-reader-text\"> (s\u2019ouvre sur ClinicalTrials.gov)<\/span><\/a><\/h3><p class=\"aa-trial-card__summary\">The primary purpose of this study is to identify the recommended phase 2 dose (RP2D[s]) and schedule(s) to be safe for JNJ-79635322 in Part\u2026<\/p><dl class=\"aa-trial-card__facts\"><div><dt>\u00c9tude<\/dt><dd>Interventionnelle (traitement)<\/dd><\/div><div><dt>Phase<\/dt><dd>Phase 1<\/dd><\/div><div><dt>Promoteur<\/dt><dd>Janssen Research &amp; Development, LLC<\/dd><\/div><\/dl><p class=\"aa-trial-card__places\"><span class=\"screen-reader-text\">Recrute en : <\/span><span class=\"aa-trial-place\">Belgium<\/span><span class=\"aa-trial-place\">France<\/span><span class=\"aa-trial-place\">Japan<\/span><span class=\"aa-trial-place\">Netherlands<\/span><span class=\"aa-trial-place aa-trial-place--more\">+3<\/span><\/p><p class=\"aa-trial-card__foot\"><span class=\"aa-trial-card__nct\">NCT05652335<\/span><span class=\"aa-trial-card__updated\">Mis \u00e0 jour le 3 novembre 2026<\/span><\/p><\/article><article class=\"aa-trial-card\"><p class=\"aa-trial-card__flags\"><span class=\"aa-trial-status aa-trial-status--recruiting\">Recrute<\/span><span class=\"aa-trial-type\">AL (cha\u00eenes l\u00e9g\u00e8res)<\/span><\/p><h3 class=\"aa-trial-card__title\"><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07224672\" target=\"_blank\" rel=\"noopener noreferrer\">A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis<span class=\"screen-reader-text\"> (s\u2019ouvre sur ClinicalTrials.gov)<\/span><\/a><\/h3><p class=\"aa-trial-card__summary\">The study aims to evaluate the efficacy and safety of belantamab mafodotin in combination with cyclophosphamide, bortezomib, and dexamethasone in adult participants with newly\u2026<\/p><dl class=\"aa-trial-card__facts\"><div><dt>\u00c9tude<\/dt><dd>Interventionnelle (traitement)<\/dd><\/div><div><dt>Phase<\/dt><dd>Phase 2<\/dd><\/div><div><dt>Promoteur<\/dt><dd>GlaxoSmithKline<\/dd><\/div><\/dl><p class=\"aa-trial-card__places\"><span class=\"screen-reader-text\">Recrute en : <\/span><span class=\"aa-trial-place\">Australia<\/span><span class=\"aa-trial-place\">United Kingdom<\/span><span class=\"aa-trial-place\">United States<\/span><\/p><p class=\"aa-trial-card__foot\"><span class=\"aa-trial-card__nct\">NCT07224672<\/span><span class=\"aa-trial-card__updated\">Mis \u00e0 jour le 3 novembre 2026<\/span><\/p><\/article><article class=\"aa-trial-card\"><p class=\"aa-trial-card__flags\"><span class=\"aa-trial-status aa-trial-status--not-yet-recruiting\">Pas encore ouverte<\/span><span class=\"aa-trial-type\">ATTR (transthyr\u00e9tine)<\/span><\/p><h3 class=\"aa-trial-card__title\"><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05974644\" target=\"_blank\" rel=\"noopener noreferrer\">Southeastern ATTR Amyloidosis Consortium: SEATTRAC Family Registry<span class=\"screen-reader-text\"> (s\u2019ouvre sur ClinicalTrials.gov)<\/span><\/a><\/h3><p class=\"aa-trial-card__summary\">The study design is a prospective registry including asymptomatic and symptomatic patients who carry a pathogenic TTR mutation. The study will enroll patients who\u2026<\/p><dl class=\"aa-trial-card__facts\"><div><dt>\u00c9tude<\/dt><dd>Observationnelle (registre, imagerie)<\/dd><\/div><div><dt>Promoteur<\/dt><dd>Virginia Commonwealth University<\/dd><\/div><\/dl><p class=\"aa-trial-card__places\"><span class=\"screen-reader-text\">Recrute en : <\/span><span class=\"aa-trial-place\">United States<\/span><\/p><p class=\"aa-trial-card__foot\"><span class=\"aa-trial-card__nct\">NCT05974644<\/span><span class=\"aa-trial-card__updated\">Mis \u00e0 jour le 3 novembre 2026<\/span><\/p><\/article><article class=\"aa-trial-card\"><p class=\"aa-trial-card__flags\"><span class=\"aa-trial-status aa-trial-status--recruiting\">Recrute<\/span><span class=\"aa-trial-type\">ATTR (transthyr\u00e9tine)<\/span><\/p><h3 class=\"aa-trial-card__title\"><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06845644\" target=\"_blank\" rel=\"noopener noreferrer\">Longitudinal Quantitative Neuromuscular MRI in Neuropathic Patients<span class=\"screen-reader-text\"> (s\u2019ouvre sur ClinicalTrials.gov)<\/span><\/a><\/h3><p class=\"aa-trial-card__summary\">The pathophysiological process common to neuropathies is fatty replacement of muscle tissue, more commonly known as intramuscular fat fraction (F.F). MRI is an imaging\u2026<\/p><dl class=\"aa-trial-card__facts\"><div><dt>\u00c9tude<\/dt><dd>Interventionnelle (traitement)<\/dd><\/div><div><dt>Promoteur<\/dt><dd>Assistance Publique Hopitaux De Marseille<\/dd><\/div><\/dl><p class=\"aa-trial-card__places\"><span class=\"screen-reader-text\">Recrute en : <\/span><span class=\"aa-trial-place\">France<\/span><\/p><p class=\"aa-trial-card__foot\"><span class=\"aa-trial-card__nct\">NCT06845644<\/span><span class=\"aa-trial-card__updated\">Mis \u00e0 jour le 29 octobre 2026<\/span><\/p><\/article><article class=\"aa-trial-card\"><p class=\"aa-trial-card__flags\"><span class=\"aa-trial-status aa-trial-status--not-yet-recruiting\">Pas encore ouverte<\/span><span class=\"aa-trial-type\">ATTR (transthyr\u00e9tine)<\/span><\/p><h3 class=\"aa-trial-card__title\"><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07591038\" target=\"_blank\" rel=\"noopener noreferrer\">PET\/CT Imaging in Carriers of TTR Mutations<span class=\"screen-reader-text\"> (s\u2019ouvre sur ClinicalTrials.gov)<\/span><\/a><\/h3><p class=\"aa-trial-card__summary\">The purpose of this study is to determine if TTR gene carriers have early signs of a type of heart disease called amyloidosis using\u2026<\/p><dl class=\"aa-trial-card__facts\"><div><dt>\u00c9tude<\/dt><dd>Observationnelle (registre, imagerie)<\/dd><\/div><div><dt>Promoteur<\/dt><dd>University of Texas Southwestern Medical Center<\/dd><\/div><\/dl><p class=\"aa-trial-card__places\"><span class=\"screen-reader-text\">Recrute en : <\/span><span class=\"aa-trial-place\">United States<\/span><\/p><p class=\"aa-trial-card__foot\"><span class=\"aa-trial-card__nct\">NCT07591038<\/span><span class=\"aa-trial-card__updated\">Mis \u00e0 jour le 29 octobre 2026<\/span><\/p><\/article><\/div><nav class=\"aa-trial-pager\" aria-label=\"Pages de la liste des essais\"><span aria-current=\"page\" class=\"page-numbers current\">1<\/span><a class=\"page-numbers\" href=\"https:\/\/amyloidosisalliance.pacom1.com\/fr\/?t_page=2\">2<\/a><span class=\"page-numbers dots\">\u2026<\/span><a class=\"page-numbers\" href=\"https:\/\/amyloidosisalliance.pacom1.com\/fr\/?t_page=17\">17<\/a><a class=\"next page-numbers\" href=\"https:\/\/amyloidosisalliance.pacom1.com\/fr\/?t_page=2\">Suivant<\/a><\/nav><div class=\"aa-trial-registry\"><p class=\"aa-trial-registry__text\">Cette liste ne couvre que les \u00e9tudes sur l\u2019amylose ouvertes ou sur le point d\u2019ouvrir. Le registre recense toutes les \u00e9tudes, y compris celles d\u00e9j\u00e0 termin\u00e9es.<\/p><div class=\"wp-block-button aa-btn aa-btn--teal\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/clinicaltrials.gov\/\" target=\"_blank\" rel=\"noopener noreferrer\">Rechercher toutes les \u00e9tudes sur ClinicalTrials.gov<span class=\"screen-reader-text\"> (s\u2019ouvre dans un nouvel onglet)<\/span><\/a><\/div><\/div><p class=\"aa-trial-source\">Source : ClinicalTrials.gov (U.S. National Library of Medicine). Liste r\u00e9cup\u00e9r\u00e9e pour la derni\u00e8re fois le 7 novembre 2026. <a href=\"https:\/\/clinicaltrials.gov\/\" target=\"_blank\" rel=\"noopener noreferrer\">clinicaltrials.gov<\/a><\/p><\/div><\/div><\/div>\n<\/section>\n\n<section class=\"wp-block-group aa-section aa-section--forest aa-cta is-layout-flow wp-block-group-is-layout-flow\">\n<div class=\"wp-block-group aa-inner aa-narrow aa-text-center is-layout-flow wp-block-group-is-layout-flow\">\n<h2 class=\"wp-block-heading\">Vous ne savez pas par o\u00f9 commencer\u202f?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Nos associations membres connaissent les \u00e9quipes qui m\u00e8nent ces \u00e9tudes dans leur pays et peuvent vous aider \u00e0 pr\u00e9parer l\u2019\u00e9change avec votre m\u00e9decin.<\/p>\n\n\n\n<div class=\"wp-block-buttons is-content-justification-center is-layout-flex wp-container-core-buttons-is-layout-aec23bef wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button aa-btn aa-btn--primary\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/amyloidosisalliance.pacom1.com\/fr\/membres\/\">Trouver une association pr\u00e8s de chez vous<\/a><\/div>\n\n\n\n<div class=\"wp-block-button aa-btn aa-btn--ghost-paper\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/amyloidosisalliance.pacom1.com\/fr\/nous-contacter\/\">Contacter l\u2019Alliance<\/a><\/div>\n<\/div>\n<\/div>\n<\/section>\n","protected":false},"excerpt":{"rendered":"<p>Accueil\u203aEssais cliniques Recherche Essais cliniques Toutes les \u00e9tudes sur l\u2019amylose qui recrutent, vont ouvrir ou recrutent sur invitation, partout dans le monde, directement issues de ClinicalTrials.gov et mises \u00e0 jour chaque jour. Une information, pas un avis m\u00e9dical. L\u2019Alliance ne conduit pas ces \u00e9tudes et ne peut pas vous y inscrire. Si un essai vous [&hellip;]<\/p>\n","protected":false},"author":0,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-1488","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Essais cliniques sur l\u2019amylose qui recrutent dans le monde<\/title>\n<meta name=\"description\" content=\"Toutes les \u00e9tudes sur l\u2019amylose qui recrutent ou vont ouvrir, issues de ClinicalTrials.gov et mises \u00e0 jour chaque jour. Filtrez par type, pays et statut.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/amyloidosisalliance.pacom1.com\/fr\/essais-cliniques\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Essais cliniques sur l\u2019amylose qui recrutent dans le monde\" \/>\n<meta property=\"og:description\" content=\"Toutes les \u00e9tudes sur l\u2019amylose qui recrutent ou vont ouvrir, issues de ClinicalTrials.gov et mises \u00e0 jour chaque jour. Filtrez par type, pays et statut.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/amyloidosisalliance.pacom1.com\/fr\/essais-cliniques\/\" \/>\n<meta property=\"og:site_name\" content=\"Amyloidosis Alliance\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/AmyloidosisAlliance\/\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-29T09:06:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/amyloidosisalliance.pacom1.com\/wp-content\/uploads\/2026\/09\/hans-reniers-lQGJCMY5qcM-unsplash-scaled-e1788792920766.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1707\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@amyloidosisa\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/amyloidosisalliance.pacom1.com\\\/fr\\\/essais-cliniques\\\/\",\"url\":\"https:\\\/\\\/amyloidosisalliance.pacom1.com\\\/fr\\\/essais-cliniques\\\/\",\"name\":\"Essais cliniques sur l\u2019amylose qui recrutent dans le monde\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/amyloidosisalliance.pacom1.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/amyloidosisalliance.pacom1.com\\\/fr\\\/essais-cliniques\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/amyloidosisalliance.pacom1.com\\\/fr\\\/essais-cliniques\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/amyloidosisalliance.pacom1.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/hans-reniers-lQGJCMY5qcM-unsplash-scaled-e1788792920766.jpg\",\"datePublished\":\"2026-09-07T14:16:46+00:00\",\"dateModified\":\"2026-09-29T09:06:38+00:00\",\"description\":\"Toutes les \u00e9tudes sur l\u2019amylose qui recrutent ou vont ouvrir, issues de ClinicalTrials.gov et mises \u00e0 jour chaque jour. Filtrez par type, pays et statut.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/amyloidosisalliance.pacom1.com\\\/fr\\\/essais-cliniques\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/amyloidosisalliance.pacom1.com\\\/fr\\\/essais-cliniques\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/amyloidosisalliance.pacom1.com\\\/fr\\\/essais-cliniques\\\/#primaryimage\",\"url\":\"https:\\\/\\\/amyloidosisalliance.pacom1.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/hans-reniers-lQGJCMY5qcM-unsplash-scaled-e1788792920766.jpg\",\"contentUrl\":\"https:\\\/\\\/amyloidosisalliance.pacom1.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/hans-reniers-lQGJCMY5qcM-unsplash-scaled-e1788792920766.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/amyloidosisalliance.pacom1.com\\\/fr\\\/essais-cliniques\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/amyloidosisalliance.pacom1.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Essais cliniques\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/amyloidosisalliance.pacom1.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/amyloidosisalliance.pacom1.com\\\/fr\\\/\",\"name\":\"Amyloidosis Alliance\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/amyloidosisalliance.pacom1.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/amyloidosisalliance.pacom1.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/amyloidosisalliance.pacom1.com\\\/fr\\\/#organization\",\"name\":\"Amyloidosis Alliance\",\"url\":\"https:\\\/\\\/amyloidosisalliance.pacom1.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/amyloidosisalliance.pacom1.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/amyloidosisalliance.pacom1.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/logo.png\",\"contentUrl\":\"https:\\\/\\\/amyloidosisalliance.pacom1.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/logo.png\",\"width\":252,\"height\":252,\"caption\":\"Amyloidosis Alliance\"},\"image\":{\"@id\":\"https:\\\/\\\/amyloidosisalliance.pacom1.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/AmyloidosisAlliance\\\/\",\"https:\\\/\\\/x.com\\\/amyloidosisa\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Essais cliniques sur l\u2019amylose qui recrutent dans le monde","description":"Toutes les \u00e9tudes sur l\u2019amylose qui recrutent ou vont ouvrir, issues de ClinicalTrials.gov et mises \u00e0 jour chaque jour. Filtrez par type, pays et statut.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/amyloidosisalliance.pacom1.com\/fr\/essais-cliniques\/","og_locale":"fr_FR","og_type":"article","og_title":"Essais cliniques sur l\u2019amylose qui recrutent dans le monde","og_description":"Toutes les \u00e9tudes sur l\u2019amylose qui recrutent ou vont ouvrir, issues de ClinicalTrials.gov et mises \u00e0 jour chaque jour. Filtrez par type, pays et statut.","og_url":"https:\/\/amyloidosisalliance.pacom1.com\/fr\/essais-cliniques\/","og_site_name":"Amyloidosis Alliance","article_publisher":"https:\/\/www.facebook.com\/AmyloidosisAlliance\/","article_modified_time":"2026-09-29T09:06:38+00:00","og_image":[{"width":1707,"height":1707,"url":"https:\/\/amyloidosisalliance.pacom1.com\/wp-content\/uploads\/2026\/09\/hans-reniers-lQGJCMY5qcM-unsplash-scaled-e1788792920766.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@amyloidosisa","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/amyloidosisalliance.pacom1.com\/fr\/essais-cliniques\/","url":"https:\/\/amyloidosisalliance.pacom1.com\/fr\/essais-cliniques\/","name":"Essais cliniques sur l\u2019amylose qui recrutent dans le monde","isPartOf":{"@id":"https:\/\/amyloidosisalliance.pacom1.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/amyloidosisalliance.pacom1.com\/fr\/essais-cliniques\/#primaryimage"},"image":{"@id":"https:\/\/amyloidosisalliance.pacom1.com\/fr\/essais-cliniques\/#primaryimage"},"thumbnailUrl":"https:\/\/amyloidosisalliance.pacom1.com\/wp-content\/uploads\/2026\/09\/hans-reniers-lQGJCMY5qcM-unsplash-scaled-e1788792920766.jpg","datePublished":"2026-09-07T14:16:46+00:00","dateModified":"2026-09-29T09:06:38+00:00","description":"Toutes les \u00e9tudes sur l\u2019amylose qui recrutent ou vont ouvrir, issues de ClinicalTrials.gov et mises \u00e0 jour chaque jour. Filtrez par type, pays et statut.","breadcrumb":{"@id":"https:\/\/amyloidosisalliance.pacom1.com\/fr\/essais-cliniques\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/amyloidosisalliance.pacom1.com\/fr\/essais-cliniques\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/amyloidosisalliance.pacom1.com\/fr\/essais-cliniques\/#primaryimage","url":"https:\/\/amyloidosisalliance.pacom1.com\/wp-content\/uploads\/2026\/09\/hans-reniers-lQGJCMY5qcM-unsplash-scaled-e1788792920766.jpg","contentUrl":"https:\/\/amyloidosisalliance.pacom1.com\/wp-content\/uploads\/2026\/09\/hans-reniers-lQGJCMY5qcM-unsplash-scaled-e1788792920766.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/amyloidosisalliance.pacom1.com\/fr\/essais-cliniques\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/amyloidosisalliance.pacom1.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Essais cliniques"}]},{"@type":"WebSite","@id":"https:\/\/amyloidosisalliance.pacom1.com\/fr\/#website","url":"https:\/\/amyloidosisalliance.pacom1.com\/fr\/","name":"Amyloidosis Alliance","description":"","publisher":{"@id":"https:\/\/amyloidosisalliance.pacom1.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/amyloidosisalliance.pacom1.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/amyloidosisalliance.pacom1.com\/fr\/#organization","name":"Amyloidosis Alliance","url":"https:\/\/amyloidosisalliance.pacom1.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/amyloidosisalliance.pacom1.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/amyloidosisalliance.pacom1.com\/wp-content\/uploads\/2026\/09\/logo.png","contentUrl":"https:\/\/amyloidosisalliance.pacom1.com\/wp-content\/uploads\/2026\/09\/logo.png","width":252,"height":252,"caption":"Amyloidosis Alliance"},"image":{"@id":"https:\/\/amyloidosisalliance.pacom1.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/AmyloidosisAlliance\/","https:\/\/x.com\/amyloidosisa"]}]}},"_links":{"self":[{"href":"https:\/\/amyloidosisalliance.pacom1.com\/fr\/wp-json\/wp\/v2\/pages\/1488","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/amyloidosisalliance.pacom1.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/amyloidosisalliance.pacom1.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"replies":[{"embeddable":true,"href":"https:\/\/amyloidosisalliance.pacom1.com\/fr\/wp-json\/wp\/v2\/comments?post=1488"}],"version-history":[{"count":1,"href":"https:\/\/amyloidosisalliance.pacom1.com\/fr\/wp-json\/wp\/v2\/pages\/1488\/revisions"}],"predecessor-version":[{"id":1489,"href":"https:\/\/amyloidosisalliance.pacom1.com\/fr\/wp-json\/wp\/v2\/pages\/1488\/revisions\/1489"}],"wp:attachment":[{"href":"https:\/\/amyloidosisalliance.pacom1.com\/fr\/wp-json\/wp\/v2\/media?parent=1488"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}